Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Heart icon (animated) heart icon (static)
Explore more Johnson & Johnson sites:
A graphic of the flag of Australia alt
A graphic of the flag of Argentina alt
A graphic of the flag of Brazil alt
A graphic of the national flag of Canada alt
A graphic of the flag of Chile alt
A graphic of the national flag of the People's Republic of China alt
A graphic of the national flag of Colombia alt
A graphic of the national flag of Ecuador alt
A graphic of the flag of Germany alt
A graphic of the national flag of India alt
A graphic of the national flag of Japan alt
A graphic of the flag of Mexico alt
A graphic of the flag of Paraguay alt
A graphic of the flag of Peru alt
A graphic of the flag of Russia alt
Switzerland
A graphic of the flag of Switzerland alt
A graphic of the national flag of Uruguay alt
A graphic of the flag of Venezuela alt
Share

Learn More About the Phase 3 Studies of Our Investigational COVID-19 Vaccine Candidate and Our Commitment to Safety and Transparency

At Johnson & Johnson, there is no greater priority than the safety and wellbeing of the people we serve every day around the world. We are committed to providing transparent updates throughout the clinical development process of our vaccine candidate, in compliance with regulatory standards.

As recently announced alongside other biopharmaceutical companies, we pledged our ongoing commitment to our developing and testing a potential vaccine for COVID-19 in accordance with high ethical standards and sound scientific principles. Further, our COVID-19 clinical trials, and the development of all investigational products across Johnson & Johnson, are guided by protocols and standards that help ensure our trials are conducted professionally, ethically, and responsibly.

In addition to our standard oversight of safety during the course of our studies, during our Phase 3 COVID-19 vaccine candidate studies (ENSEMBLE and ENSEMBLE 2), independent, expert vaccine Safety Advisory Boards have been put in place for additional consultation and advice on safety risk management. Furthermore, the safety of the entire clinical program will be overseen by independent Data and Safety Monitoring Boards (DSMB), as described in the study protocols.

We are also committed to disclosing our data on external public registries, such as ClinicalTrials.gov and the EU Clinical Trials Register, as well as publishing our results and making both our Clinical Study Reports and clinical trial participant data available for sharing with researchers through the Yale University Open Data Access (YODA) Project.

More details on the Phase 3 studies of our COVID-19 vaccine, including the study protocol and our commitment to safety and transparency, are available below.

Learn more about the innovative ways the company is mobilizing to help combat the global outbreak caused by the novel coronavirus.
This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue